The R-RAS2 GTPase is a signaling hub in triple-negative breast cancer cell metabolism and metastatic behavior

R-RAS2 associates with CD44, CD98/LAT1, and other plasma membrane receptors to regulate metabolic activity, actin cytoskeleton reorganization, cell migration, invasion, and distant metastasis formation in TNBC. These findings establish R-RAS2 as a central driver of TNBC malignancy and highlight its potential as a promising therapeutic target, particularly in aggressive, postpartum-associated breast cancers.

Authors

Institutions

Publication Details

Journal
Journal of Hematology & Oncology
Published
2025-04-12
DOI
https://doi.org/10.1186/s13045-025-01693-3
Citations
1
Primary Topic
Cancer-related Molecular Pathways
Type
article
Field-Weighted Citation Impact
1.05

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The R-RAS2 GTPase is a signaling hub in triple-negative breast cancer cell metabolism and metastatic behavior

P. Grosso, Clara L. Oeste, Alejandro M. Hortal, Alberto Paradela et al.
1 citations
Journal of Hematology & Oncology
Cancer-related Molecular Pathways
1.05
article

The R-RAS2 GTPase is a signaling hub in triple-negative breast cancer cell metabolism and metastatic behavior

P. Grosso, Clara L. Oeste, Alejandro M. Hortal, Alberto Paradela, Isabel Fernández‐Pisonero, Claudia Cifuentes, Lydia Horndler, Xosé R. Bustelo, Jennifer Castillo, Balbino Alarcón
article en
1 citations

Abstract

R-RAS2 associates with CD44, CD98/LAT1, and other plasma membrane receptors to regulate metabolic activity, actin cytoskeleton reorganization, cell migration, invasion, and distant metastasis formation in TNBC. These findings establish R-RAS2 as a central driver of TNBC malignancy and highlight its potential as a promising therapeutic target, particularly in aggressive, postpartum-associated breast cancers.

Journal of Hematology & OncologyVol. 18(1)
Universidad de Salamanca (ES), Centro Nacional de Biotecnología (ES), Hospital Universitario Miguel Servet (ES), Light Prescriptions Innovators (Spain) (ES), Centro de Investigación del Cáncer (ES), Centro de Biología Molecular Severo Ochoa (ES), Centro de Investigación Biomédica en Red de Cáncer (ES), Universidad Autónoma de Madrid (ES)
Gilead Sciences, Fundación Ramón Areces, Comunidad de Madrid, Centre de Regulació Genòmica, Centro de Biología Molecular Severo Ochoa, European Commission, Fundación Científica Asociación Española Contra el Cáncer, Ministerio de Ciencia e Innovación, Ministerio de Ciencia y Tecnología, Centro de Investigación Biomédica en Red de Cáncer, Junta de Castilla y León, Consejo Superior de Investigaciones Científicas, Instituto de Salud Carlos III, Agencia Estatal de Investigación, Centro Nacional de Biotecnología
Good health and well-being
Openalex Percentile: Top 23%
Cancer-related Molecular Pathways
1.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.